Additionally, KMT2C/BCOR/KDM5C mutation-related survival benefit was not found in NSCLC from a non-ICB treated cohort and TCGA cohorts (Figure S5), indicating that prognostic power of KMT2C/BCOR/KDM5C mutations is restricted to NSCLC patients treated with ICB. Here, KDM5C is linked to non-small cell lung carcinoma.